Login
Israel-Hamas Conflict
Social Media
Military
Protestors
Airstrike
World Cup
Parade
Motorsports
Soccer
Donald Trump
Benjamin Netanyahu
Artificial Intelligence
War
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Optimum Strategic Communications image

News from Optimum Strategic Communications

Information about Optimum Strategic Communications

Where is Optimum Strategic Communications located?Optimum Strategic Communications's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Optimum Strategic Communications News

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Startups

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines

100% Center coverage: 5 sources
Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development of lead program SB-007 in Stargardt diseaseFunding will also advance a broader pipeline…See the Story
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills - NVIDIA (NASDAQ:NVDA), Novo Nordisk (NYSE:NVO), IQVIA Hldgs (NYSE:IQV)
Nvidia · Denmark

Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills - NVIDIA (NASDAQ:NVDA), Novo Nordisk (NYSE:NVO), IQVIA Hldgs (NYSE:IQV)

100% Center coverage: 2 sources
Founder and CEO of Nvidia Corp (NASDAQ:NVDA), Jensen Huang, announced on Wednesday that the company has inked two new large partnerships to advance its work in healthcare. The first is with European-based weight loss drug maker Novo Nordisk A/S (NYSE:NVO) to accelerate drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation's (DCAI) Gefion AI supercomputer. Also Read: Hyperfine, Nvidi…See the Story
Weekly roundup: Innovation and deals for Optimum’s clients – Optimum Strategic CommunicationsLink to: Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startupsScroll to top
Nvidia

Weekly roundup: Innovation and deals for Optimum’s clients – Optimum Strategic CommunicationsLink to: Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startupsScroll to top

SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]Read Article

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the Scientific Advisory Board AARHUS, Denmark, June 4, 20…Cancer · DenmarkSee the Story

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria – Optimum Strategic CommunicationsLink to: AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSi

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]Neuried · NeuriedRead Article

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy – Optimum Strategic CommunicationsLink to: Amber Implants Announces Successful One-Year Follow-Up Data in First-in-

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]The Hague · The HagueRead Article

Weekly roundup: Success for Optimum clients in and out of the clinic – Optimum Strategic CommunicationsLink to: Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply PartnershipScroll to top

Poolbeg granted FDA Orphan Drug Designation for POLB 001 Poolbeg announced that the US Food and Drug Administration had granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome. Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer Nucleome Therapeutics, a biotechnology company harnessing the power of non-coding […]United States · United StatesRead Article

Bionical Emas And Pharma Resources Announce Exclusive Global Clinical Trial Supply Partnership - Medical Device News Magazine

Bionical Emas secures essential oncology injectables amid rising European shortages in a strategic partnership for clinical trials.London, England · LondonSee the Story

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer – Optimum Strategic CommunicationsLink to: Hot topic: Biotech’s winte

STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor Collaboration enables Phase 1b/2 study with STORM’s lead product, STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab) in patients with NSCLC, HNSCC, melanoma, and endometrial cancer Atif Abbas, M.D. joins as Chief Medical Officer 27 […]BiotechRead Article

Hot topic: Biotech’s winter: this too shall pass – Optimum Strategic CommunicationsLink to: Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business OfficerLink to: STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evalua

Sometimes trying times just seem to go on and on. The tunnel does have an end, we know, but no light can be seen.  There have been mutterings to that effect from many in the world of biotech and life science investment over the last few months.  Private mutterings have grown into louder grumbles, despite […]BiotechRead Article

Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer – Optimum Strategic CommunicationsLink to: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin LymphomaLink to: Hot

Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect. Read more…Biotech · OxfordRead Article

Breaking News Topics Related to Optimum Strategic Communications

Novo Nordisk

Novo Nordisk

United Kingdom

United Kingdom

Denmark

Denmark

France

France

Startups

Startups

Eli Lilly

Eli Lilly

Biotech

Biotech

Medical

Medical

United States

United States

News
For You
SearchBlindspotLocal